228 related articles for article (PubMed ID: 11751506)
1. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
2. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
3. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro.
Lyne JC; Melhem MF; Finley GG; Wen D; Liu N; Deng DH; Salup R
Cancer J Sci Am; 1997; 3(1):21-30. PubMed ID: 9072304
[TBL] [Abstract][Full Text] [Related]
4. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways.
Turner BC; Zhang J; Gumbs AA; Maher MG; Kaplan L; Carter D; Glazer PM; Hurst HC; Haffty BG; Williams T
Cancer Res; 1998 Dec; 58(23):5466-72. PubMed ID: 9850080
[TBL] [Abstract][Full Text] [Related]
5. Signal transducer and activator of transcription-6 (STAT6) is a constitutively expressed survival factor in human prostate cancer.
Das S; Roth CP; Wasson LM; Vishwanatha JK
Prostate; 2007 Oct; 67(14):1550-64. PubMed ID: 17705178
[TBL] [Abstract][Full Text] [Related]
6. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions.
Rehman I; Azzouzi AR; Cross SS; Deloulme JC; Catto JW; Wylde N; Larre S; Champigneuille J; Hamdy FC
Hum Pathol; 2004 Nov; 35(11):1385-91. PubMed ID: 15668896
[TBL] [Abstract][Full Text] [Related]
7. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer.
Anttila MA; Kellokoski JK; Moisio KI; Mitchell PJ; Saarikoski S; Syrjänen K; Kosma VM
Br J Cancer; 2000 Jun; 82(12):1974-83. PubMed ID: 10864206
[TBL] [Abstract][Full Text] [Related]
8. Loss of AP-2alpha results in deregulation of E-cadherin and MMP-9 and an increase in tumorigenicity of colon cancer cells in vivo.
Schwartz B; Melnikova VO; Tellez C; Mourad-Zeidan A; Blehm K; Zhao YJ; McCarty M; Adam L; Bar-Eli M
Oncogene; 2007 Jun; 26(28):4049-58. PubMed ID: 17224907
[TBL] [Abstract][Full Text] [Related]
9. Over expression of ID-1 in prostate cancer.
Ouyang XS; Wang X; Lee DT; Tsao SW; Wong YC
J Urol; 2002 Jun; 167(6):2598-602. PubMed ID: 11992094
[TBL] [Abstract][Full Text] [Related]
10. P-Cadherin is a basal cell-specific epithelial marker that is not expressed in prostate cancer.
Jarrard DF; Paul R; van Bokhoven A; Nguyen SH; Bova GS; Wheelock MJ; Johnson KR; Schalken J; Bussemakers M; Isaacs WB
Clin Cancer Res; 1997 Nov; 3(11):2121-8. PubMed ID: 9815605
[TBL] [Abstract][Full Text] [Related]
11. Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1.
Degeorges A; Wang F; Frierson HF; Seth A; Chung LW; Sikes RA
Cancer Res; 1999 Jun; 59(12):2787-90. PubMed ID: 10383131
[TBL] [Abstract][Full Text] [Related]
12. Amphiregulin expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 93 cases.
Bostwick DG; Qian J; Maihle NJ
Prostate; 2004 Feb; 58(2):164-8. PubMed ID: 14716741
[TBL] [Abstract][Full Text] [Related]
13. Up-regulation of insulin-like growth factor axis components in human primary prostate cancer correlates with tumor grade.
Liao Y; Abel U; Grobholz R; Hermani A; Trojan L; Angel P; Mayer D
Hum Pathol; 2005 Nov; 36(11):1186-96. PubMed ID: 16260272
[TBL] [Abstract][Full Text] [Related]
14. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model.
Bonkhoff H; Remberger K
Prostate; 1996 Feb; 28(2):98-106. PubMed ID: 8604398
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines.
Pflug BR; Onoda M; Lynch JH; Djakiew D
Cancer Res; 1992 Oct; 52(19):5403-6. PubMed ID: 1382843
[TBL] [Abstract][Full Text] [Related]
16. Appearance of angiotensin II expression in non-basal epithelial cells is an early feature of malignant change in human prostate.
Louis SN; Wang L; Chow L; Rezmann LA; Imamura K; MacGregor DP; Casely D; Catt KJ; Frauman AG; Louis WJ
Cancer Detect Prev; 2007; 31(5):391-5. PubMed ID: 18031950
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.
Wang JC; Bégin LR; Bérubé NG; Chevalier S; Aprikian AG; Gourdeau H; Chevrette M
Clin Cancer Res; 2007 Apr; 13(8):2354-61. PubMed ID: 17406028
[TBL] [Abstract][Full Text] [Related]
18. Localization of immunoreactive HIF-1alpha and HIF-2alpha in neuroendocrine cells of both benign and malignant prostate glands.
Monsef N; Helczynski L; Lundwall A; Påhlman S;
Prostate; 2007 Aug; 67(11):1219-29. PubMed ID: 17562539
[TBL] [Abstract][Full Text] [Related]
19. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer.
Zhigang Z; Wenlv S
Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669
[TBL] [Abstract][Full Text] [Related]
20. N-cadherin switching occurs in high Gleason grade prostate cancer.
Jaggi M; Nazemi T; Abrahams NA; Baker JJ; Galich A; Smith LM; Balaji KC
Prostate; 2006 Feb; 66(2):193-9. PubMed ID: 16173043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
